Olmewon Plus 40 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg. This formulation is designed to provide effective management of hypertension by utilizing three complementary mechanisms of action. Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance and lowering blood pressure. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, further aiding in blood pressure reduction and improving myocardial oxygen delivery. Hydrochlorothiazide, a thiazide diuretic, enhances sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to decreased blood volume and pressure. The combined action of these agents provides a synergistic effect, improving blood pressure control in patients who may not achieve target levels with monotherapy or dual therapy. Olmewon Plus 40 is indicated for the treatment of essential hypertension and may reduce the risk of cardiovascular events associated with elevated blood pressure. It should be used under medical supervision with appropriate monitoring of renal function, electrolytes, and blood pressure.